Gastrointestinal Cancer | Specialty

The Complexities of Hepatocellular Carcinoma

October 31st 2016

Dr. O'Reilly on Resistance to Immunotherapy in Pancreatic Cancer

October 29th 2016

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses resistance to immunotherapy in patients with pancreatic cancer.

Dr. Maria Ignez Braghiroli on Impact of Tumor Side in mCRC

October 28th 2016

​Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with metastatic colorectal cancer (CRC) harboring NRAS mutations.

Dr. Braghiroli on the Current and Future Treatment Landscape in CRC

October 26th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses what the current treatment landscape looks like for patients with colorectal cancer, as well as what the future may hold.

Dr. Heinemann on the Use of Depth of Response and RECIST in CRC

October 24th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, compares the use of depth of response and RECIST criteria to measure responses in patients with colorectal cancer.

Study Explores Mutation Discordance Between Primary, Metastatic Sites in CRC

October 20th 2016

Mutation discordance between primary and metastatic sites in colorectal cancer may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.

Dr. El-Khoueiry on Evolving Role of Immunotherapy in HCC

October 19th 2016

Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the role that immunotherapy currently plays, and will continue to play, in the treatment landscape of hepatocellular carcinoma (HCC).

Left-Sided CRC Survival Advantage May Be Dependent on Stage

October 19th 2016

The correlation between tumor location and improved survival varies based on stage of disease in patients with metastatic colorectal cancer.

Dr. Mikhail Fedyanin on Mutation Discordance in CRC

October 19th 2016

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC).

Dr. Pietrantonio on the Design and Rationale Behind a Nomogram to Predict Survival Rates in CRC

October 18th 2016

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that can predict 12-week survival rates for patients with colorectal cancer.

EC Approves Liposomal Irinotecan for Pancreatic Cancer

October 18th 2016

The European Commission has approved pegylated liposomal irinotecan in combination with fluorouracil and leucovorin for patients with metastatic pancreatic adenocarcinoma following progression on a gemcitabine-based therapy.

Dr. Braghiroli on Individualization of Treatment in CRC

October 13th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses the ways in which treatment can be individualized for patients with colorectal cancer depending on the mutations they may harbor.

Expert Sheds Light on Identifying "Lynch-Like Syndrome" in Patients With dMMR Rectal Cancer

October 12th 2016

To properly manage patients with DNA mismatch repair deficiency rectal cancer, one must have a well-rounded understanding of the molecular and clinical causes and risks associated with this subgroup of patients.

Dr. Venook on Looking Ahead at Treatment for CRC

October 11th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses future steps for treatment of patients with colorectal cancer.

Dr. Berger on Benefits of New Screening Test for CRC

October 11th 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses Cologuard screening test for colorectal cancer (CRC).

Dr. Braghiroli on Clinical Characteristics of NRAS-Mutant CRC

October 9th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with NRAS-mutant metastatic colorectal cancer (mCRC) during an interview at the 2016 ESMO Congress.

Dr. Bruix on the Phase III RESORCE Trial in HCC

October 8th 2016

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the results of the phase III RESORCE trial in hepatocellular carcinoma (HCC) during an interview at the 2016 ESMO Congress.

Regorafenib Shows Clinical Benefit in Patients with HCC Who Progress on Sorafenib

October 8th 2016

The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma who are unsuitable for loco-regional therapy and have progressed on sorafenib.

Dr. Heinemann on Implications of SIRFLOX Study for mCRC

October 7th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the broad clinical implications of the SIRFLOX findings for patients with metastatic colorectal cancer (mCRC).

Dr. Tempero on the HALO 301 Trial for Pancreatic Cancer

September 29th 2016

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the HALO 301 trial, which is exploring the addition of PEGPH20 to gemcitabine and albumin-bound paclitaxel as a potential treatment for patients with pancreatic adenocarcinoma.